Section Arrow
Quote
KPTI.NASDAQ
- Karyopharm Therapeutics Inc.
Quotes are at least 15-min delayed:2025/11/16 15:33 EST
Regular Hours
Last
 5.68
+0.18 (+3.27%)
Day High 
5.85 
Prev. Close
5.5 
1-M High
6.75 
Volume 
95.34K 
Bid
5.68
Ask
5.73
Day Low
5.4 
Open
5.4 
1-M Low
5.01 
Market Cap 
93.78M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.53 
20-SMA 5.88 
50-SMA 6.07 
52-W High 13.2 
52-W Low 3.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-14.70/-4.87
Enterprise Value
263.44M
Balance Sheet
Book Value Per Share
-15.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
145.24M
Operating Revenue Per Share
8.55
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 15:33 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.